NCDB Data Release
October 19, 2016
The Commission on Cancer (CoC), a program of the American College of Surgeons (ACoS), recognizes cancer care programs for their commitment to providing comprehensive, high-quality, and multidisciplinary patient centered care.
A Cancer Program Practice Profile Report (CP3R) has been newly released by the Commission on Cancer and American College of Surgeons from the National Cancer Database.
This report offers local providers comparative information to assess adherence to and consideration of standard of care therapies for major cancers. Providence Little Company of Mary Torrance would like to share our outcomes with you to show you how we compare to the local and national databases.
Providence Little Company of Mary Torrance’s performance rate on breast cancer for Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage II or III hormone receptor negative breast cancer for 2013 was at 100%. This goal was achieved through collaborative efforts by our physicians and breast nurse navigators working together to ensure timely and efficient care for our mutual patients.
Cancer care at Providence Little Company of Mary Medical Center Torrance ›